FLORHAM PARK, N.J., Sept. 16, 2019 /PRNewswire/ -- Exeltis USA, Inc. a division of Insud Pharma (headquartered in Madrid, Spain) today announced the commercial launch of its oral contraceptive tablet ...

The FDA has torn into Exeltis over a social media sponsored post for birth control pill Slynd, lambasting the drugmaker for leaving out all the risk information, making misleading efficacy claims and ...

Women's health pharma Exeltis USA has been reprimanded by the FDA for making a Facebook post that promoted its birth control product Slynd, overstating its efficacy and failing to mention potential ...

This partnership underscores the complementarity of expertise between Theranexus, with its specialized drug development capabilities, and Exeltis / Insud Pharma group - a global pharmaceutical company ...

The Food and Drug Administration (FDA) has taken a firm stance against misleading advertising practices by issuing a warning to Exeltis, the manufacturer of the progesterone-only birth control pill, ...

Drospirenone Only Pill (DOP) is the first research novel product approved by the European Health Authorities for Exeltis and the entire Insud Pharma group DOP is safer than combined contraceptives ...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, has ...

The deal sets the entry of the Spanish company into the Turkish market and is part of its strategic objective of acquiring an international scale. It will increase Exeltis sales thanks to its improved ...

New Delhi: Lupin and Exeltis Healthcare announced that the Spanish Ministry of Health (MSCBC) has approved the reimbursement of Lupin’s NaMuscla (mexiletine) for the symptomatic treatment of myotonia ...

Glenmark Pharmaceuticals and its U.S. subsidiary were hit with a patent infringement lawsuit on Nov. 6 in New Jersey District Court. The action, brought by Walsh Pizzi O'Reilly Falanga and Fish & ...